Polyrizon Ltd. (PLRZ) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, PLRZ carries an RQD Score of 30 and a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are scored as follows: Fundamental Cash Engine 5/20 (ROIC -25.1%; FCF yield -20.74%), Whale/13F Flow 5/20 (institutional accumulation and options positioning), Insider Conviction 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 7/20 (beta 1.0; sector sensitivity), and Forensic Balance Sheet 10/20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5). The lowest-scoring pillars are the cash engine and insider conviction, which indicates that the company is not currently generating positive returns on capital or free cash flow, and that insider activity in the source data does not offer support. The forensic balance sheet pillar is the highest of the five, but a Piotroski F-Score of 1 out of 9 signals weak financial quality on the scoring model's own terms. For a prospective investor, the upside case rests on factors not captured in the reported fundamentals, while the valuation tradeoff is that the price of $9 sits against negative ROIC and negative free cash flow yield. Investors should treat the rating as a forensic caution flag rather than a valuation signal.

Per the profile section, Polyrizon Ltd. (PLRZ) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. The profile lists a market capitalization of $0.0B, which conflicts with the $21.9M market cap reported in market data. The source data does not describe specific products, customers, or revenue model. Revenue is reported as $0.0M across all listed periods.

Per the SEC financials, reported operating and net losses widened from FY 2023 through FY 2025, with operating income moving from $-0.6M to $-6.2M. Gross, operating, and net margins are each reported as 0%, consistent with no reported revenue. Per the market data, ROIC is -25.1%, and per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9. Cash declined from $2.6M in FY 2024 to $1.3M in FY 2025, and debt is reported as N/A, with Debt/Equity of 0.5 per the Roarable RQD rating.

Per the recent news section, the most recent headlines describe completion of enrollment in an experimental nasal allergy barrier study, with all 120 participants reported as enrolled across five U.S. sites. Other items are technical price commentary on the stock, including references to a $10.00 level, a $9.44 level, and a 4.56% rise to $9.00. A Traders Union price-prediction piece covering 2026 and 2030–2040 is also listed. Risk watch items include that the enrollment headlines are classified as market wire and the source data does not disclose study endpoints or timelines. The Butterfly Supply-Chain Graph reports a LIQUIDITY_TAILWIND signal with a severity score of 94 and a BEARISH direction, a Macro Tailwind Score of 18/100, and a 6.00x True Net Liquidity Elasticity with r = +0.17. The graph's brief notes a True Net Liquidity Index of $5,745.73B with a -0.64% 4-week rate of change and High-Yield OAS of +2 bps.

• What products or services generate the company's revenue, given that reported revenue is $0.0M across all periods?
• What are the endpoints, timelines, and regulatory pathway for the nasal allergy barrier study, and how are they funded?
• The profile reports a $0.0B market capitalization while market data reports $21.9M. Which figure is correct?
• What is the company's cash runway given FY 2025 free cash flow of $-4.5M and year-end cash of $1.3M?
• What drove the decline in Piotroski F-Score to 1/9, and what components of the forensic balance sheet score are weakest?